Table 2

Endovascular procedure-related data

Total n=90 patients/90 treated aneurysms/104 stents used/91 stents placed
Number of aneurysms treated per patient, n (%)90 (100.00)
 190 (100.00)
Number of stents used per patient, n (%)90 (100.00)
 176 (84.44)
 214 (15.56)
Number of stents placed per patient, n (%)90 (100.00)
 03 (3.33)
 183 (92.22)
 2 (dual stent/Y-stenting)4 (4.44)
Reasons for non-deployment of stents, n/total stents used12/104
 Inappropriate selection of stent size3/104
 Failure of deployment during positionning3/104
 Technical issues: premature detachment2/104
 Non-use due to sterility issues4/104
Type of stent placed, n (%)91 (100.00)
 LVIS14 (15.38)
 LVIS Jr77 (84.62)
Treatment technique, n (%)90 (100.00)
 Coiling passing through the stent LVIS (trans-stent)12 (13.33)
 Coiling with the jailing technique20 (22.22)
 Coiling and subsequent deployment of the LVIS stent (post-coiling)3 (3.33)
 Balloon-assisted coiling before LVIS deployment47 (52.22)
 Y-stenting4 (4.45)
 Other4 (4.45)
Number of used coils, mean±SD (median)6.40±3.91 (6.00)
Use of other material, n (%)90 (100.00)
 Distal catheter30 (33.33)
 Guiding catheter90 (100.00)
 Catheter with balloon53 (58.89)
Catheter positioning success for deployed stents, n (%)91 (100.00)
Antiplatelet regimen before endovascular treatment, n (%)90 (100.00)
 Acetylsalicylic acid*56 (62.22)
 Clopidogrel (Plavix)72 (80.00)
 Prasugrel (Efient)15 (16.67)
Antiplatelet regimen during endovascular procedure, n (%)90 (100.00)
 Acetylsalicylic acid*32 (35.56)
 Clopidogrel (Plavix)1 (1.11)
 Heparin62 (68.89)
 Abciximab (Reopro)2 (2.22)
Antiplatelet regimen after endovascular treatment, n (%)87 (96.67)
 Acetylsalicylic acid*83 (92.22)
 Clopidogrel (Plavix)68 (75.56)
 Prasugrel (Efient)14 (15.56)

  • *Aspirin and/or Aspegic and/or Kardegic.